← Eichor
Condition: High Risk Locally Advanced Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: High Risk Locally Advanced

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression
Phase 2 · 1 location(s) · Sixth Affiliated Hospital, Sun Yat-sen University · NCT07176182Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
Phase 3 · 205 location(s) · AstraZeneca · NCT06079671Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi)
Phase 3 · 1 location(s) · Peking University Cancer Hospital & Institute · NCT06229041PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsa
Phase 3 · 1 location(s) · Centre Hospitalier Universitaire Dijon · NCT06762405AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
Phase 1 · 22 location(s) · Amgen · NCT07403721RW Study of Adjuvant Radiotherapy in Locally Advanced Thyroid Cancer
Phase N/A · 1 location(s) · Fudan University · NCT06524167Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and
Phase 2 · 1 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT07016230Hyperthermia With Chemoradiotherapy in Rectal Cancer
NA · 2 location(s) · University Hospital Tuebingen · NCT06831981Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06170710Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT03926338Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06903858Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Phase 1/Phase 2 · 66 location(s) · Genmab · NCT05579366Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Phase 1 · 30 location(s) · Calico Life Sciences LLC · NCT04777994A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nas
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07392320Relugolix + Enzalutamide Study in High-Risk Prostate Cancer
Phase 1 · 1 location(s) · University of Oklahoma · NCT06130995First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Incl
Phase 1 · 6 location(s) · Accent Therapeutics · NCT06799065Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
Phase 2 · 1 location(s) · The Affiliated Nanjing Drum Tower Hospital of Nanjing Univer · NCT05406999Safety and Early Efficacy of Radical Prostatectomy for Newly Diagnosed Very High Risk Locally Advanced and Oligometastat
NA · 1 location(s) · Medical University of Vienna · NCT02971358Evaluation of Ultraaccelerated High Dose Rate Intrauterine Interventional Radiotherapy
Phase N/A · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT06398938Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance C
Phase 3 · 301 location(s) · National Cancer Institute (NCI) · NCT07061977Pyrotinib in Women With High-risk in Early Stage Breast Cancer
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT05834764Low-Dose Weekly vs High-Dose Cisplatin
NA · 3 location(s) · London Health Sciences Centre Research Institute OR Lawson R · NCT03649048A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cis
Phase 1/Phase 2 · 1 location(s) · Shanghai 6th People's Hospital · NCT07632235Combined Postoperative Radiotherapy With Kidney Sparing Surgery for Locally Advanced High-risk Ureteral Cancer
Phase N/A · 2 location(s) · Xuesong Li · NCT06120387Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
Phase 2 · 30 location(s) · BeiGene · NCT03736889EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC
Phase 2 · 1 location(s) · Peking University Third Hospital · NCT07647289A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Phase 1/Phase 2 · 5 location(s) · 7 Hills Pharma, LLC · NCT06362369Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC
Phase 2 · 1 location(s) · Shanghai Jiao Tong University School of Medicine · NCT06500208FOG-001 in Locally Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 33 location(s) · Parabilis Medicines, Inc. · NCT05919264Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expressi
Phase 1/Phase 2 · 1 location(s) · Second Affiliated Hospital of Nanchang University · NCT07655622
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.